SRNE News and Press, Sorrento Therapeutics Inc. From 05/26/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Like the 9/11 attack or the implosion of the global financial markets in 2008, we will not soon forget the devastation of the novel coronavirus pandemic. Initially, reports about a mysterious outbreak in Wuhan, China made f...

The "Tesla Test" looks for the rare combination of forensic scores that preceded a 40% drop in TSLA stock in a prior ad-hoc study forecasting many other stock declines since. This ongoing test of 22 adverse fundamental forensic and value ratios across four accounting algorithms resume...

Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed. The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients hospitalized due to acute respiratory distress syndrome (ARDS). Given the emerge...

Sofusa is a drug delivery platform technology which delivers biologic therapies through the skin directly into the lymphatic system with potential to improve efficacy and safety and reduce the required dosing (as compared to traditional systemic or subcutaneous injections or infusions). ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’ve long been skeptical toward Ocugen (NASDAQ: OCGN ) stock. To some degree, I still am. Source: Shutterstock OCGN is pushed as a vaccine play, thanks to its partnership with India’s Bharat Biote...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips When markets realized that Ocugen (NASDAQ: OCGN ) has a vaccine that is effective against Covid-19 in India, shares surged. OCGN stock joins a list of hopeful biotechnology firms seeking to supply Covid-19 vaccines wo...

The FDA has given Sorrento Therapeutics (SRNE) the green light to commence a phase 2 study of STI-3031, a monoclonal antibody ("mAb") for advanced urothelial carcinoma.The anti-PD-L1 mAb was licensed to ImmuneOncia, a joint venture between Sorrento and South Korea-based Yuhan Corp.Immune...

STI-3031 was discovered from Sorrento’s fully human G-MAB™ library. Currently, six G-MAB antibodies are in Phase 1b through Phase 3 clinical trials in immuno-oncology and COVID-19 indications. These clinical and pre-clinical G-MAB antibodies are expected to be t...

Shares of Sorrento Therapeutics (NASDAQ: SRNE) are rising sharply on Monday and were up by 10.8% as of 1:43 p.m. EDT after jumping by as much as 14.6% earlier in the trading session. The biopharmaceutical company did not report any news, but perhaps the market is responding to comme...

Sorrento Therapeutics (SRNE) has completed enrollment in its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respiratory failure ((ARD)) or acute respiratory distress syndrome ((ARDS)).This current study (MSC-COV-1...